ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health Care • China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
bullish•Shandong Fengxiang
•13 Jun 2025 09:06

Fengxiang (9977 HK): PAG Invites Dissent After Scrapping Scrip Alternative

Evidently PAG reckons the support for the scrip is not worth the trouble. Nor critical in mass to disrupt the Offer. If illiquid arbs are your...

Logo
493 Views
Share
bullish•Tam Jai International
•09 Jun 2025 08:37

Tam Jai International (2217 HK) Privatization - The Offer Price Is Good

The Scheme Doc is out. Since the Cancellation Price of HK$1.58 represents a premium of 75.56% over the undisturbed price of HK$0.90 and a premium...

Logo
903 Views
Share
bearish•Soundwill Holdings
•26 May 2025 11:02

Soundwill (878 HK): Thoughts On The Latest Scheme Fail

The outcome for Soundwill was not a big surprise. However, expect current and future illiquid small-cap arbs to trade wide(r) if there is a whiff...

Logo
624 Views
Share
bearish•Soundwill Holdings
•25 May 2025 06:34

Soundwill Holdings (878 HK): Hard Lessons from Another HK Arbageddon

Like previous deal breaks, this one offers hard lessons and suggests that HK merger arb is increasingly fraught with risk. My estimated deal-break...

Logo
613 Views
Share
bearish•Goldlion Holdings
•11 May 2025 18:22

Goldlion Holdings (533 HK): An Unexpected HK Arbageddon

The Goldlion deal break was unexpected, and the HKEx merger arb rulebook will be rewritten. My estimated deal-break price is HK$0.953, 36.0% below...

Logo
585 Views
Share
x